Brand names: Nevirapine
23 interactions on record
Antifungals: Fluconazole* ↑Nevirapine Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events.
Source: FDA drug label - nevirapine
Fosamprenavir* ↓ Amprenavir ↑ Nevirapine Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. Fosamprenavir/Ritonavir* ↓ Amprenavir ↑ Nevirapine No dosing adjustments are required when nevirapine is co-administered with 700/100 mg of fosamprenavir/ritonavir twice daily. The combination of nevirapine administered with fosamprenavir/ritonavir once daily has not been studied.
Source: FDA drug label - nevirapine
Drug Name Effect on Concentration of Nevirapine or Concomitant Drug Clinical Comment HIV Antiviral Agents: Protease Inhibitors (PIs) Atazanavir/Ritonavir* ↓ Atazanavir ↑ Nevirapine Do not co-administer nevirapine with atazanavir because nevirapine substantially decreases atazanavir exposure and there is a potential risk for nevirapine-associated toxicity due to increased nevirapine exposures.
Source: FDA drug label - nevirapine
Alternatives to clarithromycin, such as azithromycin, should be considered.
Source: FDA drug label - nevirapine
Hepatitis C Antiviral Agents Boceprevir Plasma concentrations of boceprevir may be decreased due to induction of CYP3A4/5 by nevirapine. Nevirapine and boceprevir should not be coadministered because decreases in boceprevir plasma concentrations may result in a reduction in efficacy.
Source: FDA drug label - nevirapine
Antibiotics: Clarithromycin* ↓ Clarithromycin ↑ 14-OH clarithromycin Clarithromycin exposure was significantly decreased by nevirapine; however, 14-OH metabolite concentrations were increased. Because clarithromycin active metabolite has reduced activity against Mycobacterium avium-intracellulare complex , overall activity against this pathogen may be altered. Alternatives to clarithromycin, such as azithromycin, should be considered.
Source: FDA drug label - nevirapine
Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased.
Source: FDA drug label - nevirapine
Cancer Chemotherapy: Cyclophosphamide Plasma concentrations may be decreased.
Source: FDA drug label - nevirapine
23 Atazanavir 300/100 mg ↓ 42 (↓ 52 to ↓ 29) Atazanavir 300/100 mg ↓ 28 (↓ 40 to ↓ 14) Atazanavir 300/100 mg ↓ 72 (↓ 80 to ↓ 60) Atazanavir 400/100 mg ↓ 19 (↓ 35 to ↑ 2) Atazanavir 400/100 mg ↑ 2 (↓ 15 to ↑ 24) Atazanavir 400/100 mg ↓ 59 (↓ 73 to ↓ 40) Darunavir/Ritonavir Based on between-trial comparison.
Source: FDA drug label - nevirapine
Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased.
Source: FDA drug label - nevirapine
Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased.
Source: FDA drug label - nevirapine
Fosamprenavir* ↓ Amprenavir ↑ Nevirapine Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. Fosamprenavir/Ritonavir* ↓ Amprenavir ↑ Nevirapine No dosing adjustments are required when nevirapine is co-administered with 700/100 mg of fosamprenavir/ritonavir twice daily. The combination of nevirapine administered with fosamprenavir/ritonavir once daily has not been studied.
Source: FDA drug label - nevirapine
Indinavir* ↓ Indinavir The appropriate doses of this combination of indinavir and nevirapine with respect to efficacy and safety have not been established.
Source: FDA drug label - nevirapine
Itraconazole ↓ Itraconazole Nevirapine and itraconazole should not be administered concomitantly due to potential decreases in itraconazole plasma concentrations that may reduce efficacy of the drug.
Source: FDA drug label - nevirapine
Ketoconazole* ↓ Ketoconazole Nevirapine and ketoconazole should not be administered concomitantly because decreases in ketoconazole plasma concentrations may reduce the efficacy of the drug.
Source: FDA drug label - nevirapine
Lopinavir/Ritonavir* ↓Lopinavir Dosing in adult patients: A dose adjustment of lopinavir/ritonavir to 500/125 mg tablets twice daily or 533/133 mg (6.5 mL) oral solution twice daily is recommended when used in combination with nevirapine. Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine. Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine.
Source: FDA drug label - nevirapine
Nelfinavir* ↓Nelfinavir M8 Metabolite ↓Nelfinavir Cmin The appropriate doses of the combination of nevirapine and nelfinavir with respect to safety and efficacy have not been established.
Source: FDA drug label - nevirapine
Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased.
Source: FDA drug label - nevirapine
300 mg SD 200 mg BID 8 ↑ 1 (↓ 35 to ↑ 55) ↑ 54 (↓ 6 to ↑ 151) ↔ Nelfinavir 750 mg TID 200 mg QD x 14 days; 200 mg BID x 14 days 23 ↔ ↔ ↓ 32 (↓ 50 to ↑ 5) Nelfinavir-M8 metabolite ↓ 62 (↓ 70 to ↓ 53) ↓ 59 (↓ 68 to ↓ 48) ↓ 66 (↓74 to ↓ 55) Ritonavir 600 mg BID 200 mg QD x 14 days; 200 mg BID x 14 days 18 ↔ ↔ ↔ Stavudine 30-40 mg BID 200 mg QD x 14 days; 200 mg BID x 14 days 22 ↔ ↔ § Zalcitabine 0.125-0.25 mg TID 200 mg QD x 14 days; 200 mg BID x 14 days 6 ↔ ↔ § Zidovudine 100-200 mg TID 200 mg QD x 14 days; 200 mg BID x 14 days 11 ↓ 28 (↓ 40 to ↓ 4) ↓ 30 (↓ 51 to ↑ 14) § Other Medications AUC C max C min Clarithromycin 500 mg BID 200 mg QD x 14 days; 200 mg BID x 14 days 15 ↓ 31 (↓ 38 to ↓ 24) ↓ 23 (↓ 31 to ↓ 14) ↓ 56 (↓ 70 to ↓ 36) Metabolite 14-OH-clarithromycin ↑ 42 (↑ 16 to ↑ 73) ↑ 47 (↑ 21 to ↑ 80) ↔ Ethinyl Estradiol and Norethindrone 0.035 mg (as Ortho-Novum ® 1/35) 1 mg (as Ortho-Novum ® 1/35) 200 mg QD x 14 days; 200 mg BID x 14 days 10 ↓ 20 (↓ 33 to ↓ 3) ↔ § ↓ 19 (↓ 30 to ↓ 7) ↓ 16 (↓ 27 to ↓ 3) § Depomedroxy- Progesterone Acetate 150 mg every 3 months 200 mg QD x 14 days; 200 mg BID x 14 days 32 ↔ ↔ ↔ Fluconazole 200 mg QD 200 mg QD x 14 days; 200 mg BID x 14 days 19 ↔ ↔ ↔ Ketoconazole 400 mg QD 200 mg QD x 14 days; 200 mg BID x 14 days 21 ↓ 72 (↓ 80 to ↓ 60) ↓ 44 (↓ 58 to ↓ 27) § Methadone Individual Subject Dosing 200 mg QD x 14 days; 200 mg BID ≥ 7 days 9 In a controlled pharmacokinetic trial with 9 subjects receiving chronic methadone to whom steady-state nevirapine therapy was added, the clearance of methadone was increased by 3-fold, resulting in symptoms of withdrawal, requiring dose adjustments in 10 mg segments, in 7 of the 9 subjects.
Source: FDA drug label - nevirapine
Drug Name Effect on Concentration of Nevirapine or Concomitant Drug Clinical Comment HIV Antiviral Agents: Protease Inhibitors (PIs) Atazanavir/Ritonavir* ↓ Atazanavir ↑ Nevirapine Do not co-administer nevirapine with atazanavir because nevirapine substantially decreases atazanavir exposure and there is a potential risk for nevirapine-associated toxicity due to increased nevirapine exposures. Fosamprenavir* ↓ Amprenavir ↑ Nevirapine Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. Fosamprenavir/Ritonavir* ↓ Amprenavir ↑ Nevirapine No dosing adjustments are required when nevirapine is co-administered with 700/100 mg of fosamprenavir/ritonavir twice daily.
Source: FDA drug label - nevirapine
Saquinavir/Ritonavir The interaction between nevirapine and saquinavir/ritonavir has not been evaluated The appropriate doses of the combination of nevirapine and saquinavir/ritonavir with respect to safety and efficacy have not been established.
Source: FDA drug label - nevirapine
Telaprevir Plasma concentrations of telaprevir may be decreased due to induction of CYP3A4 by nevirapine and plasma concentrations of nevirapine may be increased due to inhibition of CYP3A4 by telaprevir. Nevirapine and telaprevir should not be coadministered because changes in plasma concentrations of nevirapine, telaprevir, or both may result in a reduction in telaprevir efficacy or an increase in nevirapine-associated adverse events.
Source: FDA drug label - nevirapine
No significant interaction was observed when tipranavir was co-administered with low-dose ritonavir and nevirapine.
Source: FDA drug label - nevirapine